Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy

Memogain® (Gln-1062) is an inactive pro-drug of galantamine, the latter being a plant alkaloid approved for the treatment of mild to moderate Alzheimer’s disease. Memogain has more than 15-fold higher bioavailability in the brain than the same doses of galantamine. In the brain, Memogain is enzymati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of molecular neuroscience 2010, Vol.40 (1-2), p.135-137
Hauptverfasser:	Maelicke, Alfred, Hoeffle-Maas, Anja, Ludwig, Juergen, Maus, Arno, Samochocki, Marek, Jordis, Ulrich, Koepke, Andreas K. E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylcholine - agonists Alzheimer Disease - drug therapy Alzheimer's disease Animal cognition Animals Biomedical and Life Sciences Biomedicine Brain - drug effects Brain - physiopathology Brain Chemistry - drug effects Cell Biology Cholinesterase Inhibitors - adverse effects Cholinesterase Inhibitors - pharmacology Cognition - drug effects Cognition Disorders - chemically induced Cognition Disorders - drug therapy Cognition Disorders - physiopathology Compliance Disease Models, Animal Dose-Response Relationship, Drug Drug dosages Drug Evaluation, Preclinical - methods Ferrets Galantamine - adverse effects Galantamine - analogs & derivatives Galantamine - pharmacology Gastrointestinal Diseases - chemically induced Humans Mice Mustela putorius furo Neurochemistry Neurology Neurosciences Proteomics Scopolamine Hydrobromide - antagonists & inhibitors Synaptic Transmission - drug effects Synaptic Transmission - physiology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!